XML 41 R31.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Information (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2023
Notes Tables |
Schedule of financial information by reportable segment | The following is financial information relating to the Company's reportable segments (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Quarter Ended
​ | ​ | ​ | September 30,
​ |  | ​ | 2023 |  | 2022
Net sales: |  | ​ | ​ |  | ​ | ​ | ​
Protein Sciences | ​ | ​ | $ | 204,655 |  | $ | 199,949
Diagnostics and Genomics | ​ | ​ |  | 72,797 | ​ |  | 69,904
Intersegment | ​ | ​ |  | (517) | ​ |  | (198)
Consolidated net sales | ​ | ​ | $ | 276,935 |  | $ | 269,655
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income: | ​ | ​ |  |  | ​ |  |
Protein Sciences | ​ | ​ | $ | 88,361 |  | $ | 85,942
Diagnostics and Genomics | ​ | ​ |  | 527 | ​ |  | 8,638
Segment operating income | ​ | ​ | $ | 88,888 | ​ | $ | 94,580
Costs recognized on sale of acquired inventory | ​ | ​ |  | (181) | ​ |  | (300)
Amortization of intangibles | ​ | ​ |  | (19,851) | ​ |  | (19,283)
Impact of partially-owned consolidated subsidiaries(1) | ​ | ​ |  | — | ​ |  | 647
Acquisition related expenses and other | ​ | ​ |  | 588 | ​ |  | (297)
Stock based compensation, inclusive of employer taxes | ​ | ​ |  | (11,494) | ​ |  | (15,458)
Restructuring costs | ​ | ​ |  | (89) | ​ |  | (2,170)
Corporate general, selling, and administrative expenses | ​ | ​ |  | (1,999) | ​ |  | (1,402)
Consolidated operating income | ​ | ​ | $ | 55,862 |  | $ | 56,317
​ (1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration